Sort
10,766 grants matching “checkpoint inhibitor”
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma
$200,000Rahul Anil Sheth · University Of Tx Md Anderson Can Ctr · R21 · FY2020 · EB
STAT1: New regulator of inflammatory Th17 and Th2 cells
$200,000Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R21 · FY2017 · AI
Peptide conjugated liposomes activate anti-tumor immunity
$200,000Debra Auguste · Northeastern University · R56 · FY2022 · CA
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft Models
$200,000Ramaswamy Govindan · Washington University · U54 · FY2022 · CA
Molecularly targeted photothermal ablation to enhance the therapeutic efficacy of immunomodulatory therapies in hepatocellular carcinoma
$200,000Rahul Anil Sheth · University Of Tx Md Anderson Can Ctr · R21 · FY2021 · EB
Flow Cytometry Core
$200,000W Martin Kast · University Of Southern California · P30 · FY2024 · CA
Immune Modulation After Allogeneic HCT
$200,000Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2022 · CA
Immune Modulation After Allogeneic HCT
$200,000Robert Jon Soiffer · Dana-Farber Cancer Inst · P01 · FY2022 · CA
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera
$199,970David E Fisher · Massachusetts General Hospital · P01 · FY2013 · CA
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera
$199,970David E Fisher · Massachusetts General Hospital · P01 · FY2016 · CA
Combinatorial Approaches to Overcoming Resistance to BRAF(V600E) Targeted Thera
$199,970David E Fisher · Massachusetts General Hospital · P01 · FY2015 · CA
Drug combination nanoparticles for advanced treatment of metastatic TNBC
$199,842Qingxin Mu · University Of Washington · R21 · FY2023 · CA
DNA MISMATCH REPAIR IN FDURD INDUCED CYTOTOXICITY
$199,740Case Western Reserve University · R01 · FY2000 · CA
Flow Cytometry Core
$199,418W Martin Kast · University Of Southern California · P30 · FY2023 · CA
Test if antitumor T cells use a putative super-enhancer in the Il1rl2-Il1rl1 intergenic region to form "innate-like" responses to cytokines
$199,375Adam J Adler · University Of Connecticut Sch Of Med/Dnt · R21 · FY2018 · AI
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS
$199,307Roswell Park Cancer Institute Corp · R01 · FY2003 · CA
Visualizing radiation-induced tumor immune responses
$199,166Anna M Wu · Beckman Research Institute/City Of Hope · R21 · FY2019 · CA
BIOCHEMICAL BASIS FOR THERAPEUTIC ACTIVITY
$199,112University Of Texas Md Anderson Can Ctr · R01 · FY2001 · CA
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
$199,098David Yoonsuk Oh · University Of California, San Francisco · K08 · FY2020 · AI
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
$199,098David Yoonsuk Oh · University Of California, San Francisco · K08 · FY2019 · AI
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
$199,098David Yoonsuk Oh · University Of California, San Francisco · K08 · FY2022 · AI
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
$199,098David Yoonsuk Oh · University Of California, San Francisco · K08 · FY2023 · AI
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
$199,098David Yoonsuk Oh · University Of California, San Francisco · K08 · FY2021 · AI
GENETICS OF CELL CYCLE &DNA DAMAGE REGULATION IN YEAST
$198,774Baylor College Of Medicine · R01 · FY2000 · GM
Targeting of Master Signaling Molecule to Restore Functions of Exhausted HIV-specific CTLs
$198,750Dongfang Liu · Rbhs-New Jersey Medical School · R21 · FY2018 · AI